GENE ONLINE|News &
Opinion
Blog

2020-11-12| Asia-PacificCOVID-19

Celltrion Announces Positive Phase 1 Results for COVID-19 Antibody Therapy

by Tyler Chen
Share To

South Korea-based Celltrion Healthcare announced the result of Phase 1 clinical trial of a monoclonal antibody treatment candidate (CT-P59) targeting SARS-COV-2 at the 2020 fall Conference of the Korean Society of Infectious Diseases on November 5th. CT-P59 has shown promise in the tolerability, safety, and efficacy of COVID-19 patients with mild symptoms. Seo Jung-jin, Chairman of Celltrion, pointed out in an MBC radio interview that “if you look at the result so far, all viruses in the body are killed in 4 to 5 days”.

 

Shown High Efficacy in Neutralizing Viruses

CT-P59 is an antibody candidate that has demonstrated high efficacy in neutralizing the SARS-CoV-2 virus, including the mutated G-variant strain (D614G variant). The medication in preclinical data exhibits a 100-fold reduction in viral load of SARS-CoV-2 and lung inflammation.

The Phase 1 clinical trial investigated the antiviral and safety effects of CT-P59. Enrolling 18 patients with mild symptoms of COVID-19, every 5 patients were respectively given 20mg/kg, 40mg/kg, or 80mg/kg of CT-P59, and the last 3 patients received a placebo.

Results demonstrated that the mean clinical recovery time in patients with CT-P59 has decreased by 44% compared to the placebo group, which means the recovery time is 44% faster. Also, patients in the trials did not require hospitalization or antiviral therapy, and no serious adverse events were identified.

 

Future Development

Currently, CT-P59 is under Phase 2 and 3 clinical trials, treating mild and moderate COVID-19 patients, and has been scheduled to verify details of mass production of the antibody treatment in September.

On Nov. 11, Chairman Seo, in an MBC radio interview, pointed out that Celltrion will “apply for conditional approval in December” if the Phase 2 clinical trial is finished in 2020 and shows “no problem in efficacy and safety.”

He said, “if you look at the result so far, all viruses in the body are killed in 4 to 5 days.” and Celltrion has manufactured the treatment for 100,000 COVID-19 patients.

By Tyler Chen

Related Article: Nanoparticle COVID-19 Vaccine Elicits Potent Neutralizing Antibodies

References
  1. https://www.celltrionhealthcare.com/en-us/board/newsdetail?modify_key=409&pagenumber=1&keyword=&keyword_type=

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
AstraZeneca’s COVID-19 Vaccine Finally Wins Full Authorization in the European Union
2022-11-01
LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!